A Phase 2 Randomized, Open-Label, Exploratory Trial of GS-5885, GS-9451 With Peginterferon Alfa 2a and Ribavirin (RBV) in Treatment-Naive Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and IL28B CC Genotype.

Trial Profile

A Phase 2 Randomized, Open-Label, Exploratory Trial of GS-5885, GS-9451 With Peginterferon Alfa 2a and Ribavirin (RBV) in Treatment-Naive Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and IL28B CC Genotype.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2015

At a glance

  • Drugs Ledipasvir (Primary) ; Vedroprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 24 Dec 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 28 Apr 2013 Interim results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
    • 23 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top